Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT03817190

Public ClinicalTrials.gov record NCT03817190. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to compare the efficacy and safety of orally administered DS107 (2g) versus placebo in the treatment of moderate to severe Atopic Dermatitis (AD). Oral DS107/Placebo capsules will be administered for 16 weeks. The study will enrol approximately 220 subjects.

Study identification

NCT ID
NCT03817190
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
DS Biopharma
Industry
Enrollment
219 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 18, 2019
Primary completion
Sep 2, 2020
Completion
Sep 2, 2020
Last update posted
Nov 27, 2022

2019 – 2020

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
DS Investigational Site 524 Birmingham Alabama 35209
DS Investigational Site 528 Huntington Beach California 92647
DS Investigational Site 502 Los Angeles California 90045
DS Investigational Site 504 San Diego California 92108
DS Investigational Site 505 San Diego California 92123
DS Investigational Site 516 Santa Ana California 92705
DS Investigational Site 501 Santa Monica California 90404
DS Investigational Site 517 Washington D.C. District of Columbia 20037
DS Investigational Site 527 Doral Florida 33122
DS Investigational Site 510 Sunrise Florida 33351
DS Investigational Site 512 Columbus Georgia 31904
DS Investigational Site 514 Skokie Illinois 60077
DS Investigational Site 513 Louisville Kentucky 40241
DS Investigational Site 519 Troy Michigan 48084
DS Investigational Site 511 Raleigh North Carolina 27612
DS Investigational Site 526 Grants Pass Oregon 97527
DS Investigational Site 521 Medford Oregon 97504
DS Investigational Site 525 Philadelphia Pennsylvania 19046
DS Investigational Site 509 Arlington Texas 76011
DS Investigational Site 506 Austin Texas 78745
DS Investigational Site 508 Cypress Texas 77433
DS Investigational Site 507 San Antonio Texas 78213
DS Investigative Site 529 Orem Utah 84058
DS Investigative Site 530 Salt Lake City Utah 84117
DS Investigational Site 523 Richmond Virginia 23224
DS Investigational Site 518 Kenosha Wisconsin 53144

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03817190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 27, 2022 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03817190 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →